Clinical Trials to Validate AI-Driven Drug Repurposing 2026
Forecasted
Cures Within Reach funds clinical trials using AI to validate repurposed therapies for unsolved diseases, prioritizing rare conditions and explainable AI workflows.
Funder: Cures Within Reach
Due Dates (Anticipated): June 2027 (Letter of Intent deadline, projected)
Funding Amounts: Up to $100,000 per trial (includes 10% institutional match); additional $5,000–$10,000 available for community engagement costs.
Summary: Supports proof-of-concept clinical trials using AI-driven approaches to validate repurposed therapies for unsolved diseases, with a focus on rare conditions and innovative, explainable AI.
Key Information: Two-stage process (LOI then full proposal); only nonprofit, academic, or health system researchers eligible.
Description
This opportunity from Cures Within Reach funds investigator-initiated, proof-of-concept Phase I or Phase IIA clinical trials that aim to validate artificial intelligence (AI)-driven drug repurposing opportunities for unsolved diseases worldwide. Proposals must utilize AI-generated data as preclinical support, with the AI workflow providing clear and explainable evidence for the repurposing hypothesis. The grant welcomes trials involving approved drugs, biologics, eligible cellular/gene therapies, or combination therapies in new indications, with a preference for rare diseases and off-patent therapies. Any type of AI model is eligible, provided it meaningfully contributes to identifying or validating repurposed therapies. The program encourages interdisciplinary collaboration, robust clinical trial design, and innovative use of AI to accelerate the development of new treatment options for conditions lacking effective solutions.
